Facemasks and Walk Distance in Pulmonary Arterial Hypertension Patients

Scott A. Helgeson, MD; Charles D. Burger, MD; John E. Moss, MD; Tonya K. Zeiger, RRT; and Bryan J. Taylor, PhD

Abstract

Little is known about the effect of wearing a facemask on the physiological and perceptual responses to exercise in patients with pulmonary arterial hypertension (PAH). We performed a single-center retrospective study to evaluate whether facemask wearing impacted distance covered, rating of perceived exertion (RPE), and arterial oxygen saturation (SpO2) during a 6-minute walk test (6MWT) in PAH patients. Forty-five patients being treated for group 1 PAH and who performed a 6MWT before and after implementation of a facemask mandate were included in the analysis. Each included patient performed a 6MWT without (test 1) and with (test 2) a facemask between October 1, 2019, and October 31, 2020. At both time points, all patients also underwent a submaximal cardiopulmonary exercise test, echocardiogram, and blood laboratory tests, with a Registry to Evaluate Early and Long-Term PAH Disease Management Lite 2.0 score calculated. The two 6MWTs were performed 81±51 days apart, and all patients were clinically stable at both testing timepoints. Six-minute walk test distance was not different between test 1 and test 2 (405±108 m vs 400±103 m, P=.81). Similarly, both end-test RPE and lowest SpO2 during the 6MWT were not different in test 1 and test 2 (RPE: 2.5±1.7 vs 2.5±2.1, P=.91; SpO2 nadir: 92.8±3.4% vs 93.3±3.3%, P=.55). Our findings show that wearing a facemask has no discernable impact on the arterial oxygen saturation and perceptual responses to exercise or exercise capacity in patients with moderate-to-severe PAH. This study reinforces the evidence that wearing a facemask is safe in PAH patients, even during exercise.

© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
performed according to standard American Thoracic Society procedures. All patients were provided with, and wore, a new level 2 procedural mask during each 6MWT (Halyard, Alpharetta, GA, USA). Arterial oxygen saturation was measured at rest, throughout the 6MWT, and for up to 5 minutes after the 6MWT using a pulse oximeter instrumented with a finger probe (Nonin PalmSAT 2500, Nonin Medical Inc, Plymouth, MN, USA); presently, we report the lowest SpO$_2$ value (ie, the nadir) recorded during the 6MWT. The RPE was obtained within 15 seconds of 6MWT termination using the Borg category-ratio scale.

At both timepoints (test 1 and test 2), all patients also underwent a submaximal cardiopulmonary exercise test (CPET), echocardiogram, and blood laboratory tests, with a REVEAL Lite 2.0 score calculated. A facemask was not worn during the submaximal CPET at either “Test 1” or “Test 2.” The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 risk assessment calculator for patients with PAH includes six noninvasive variables: New York Heart Association (NYHA) functional class, vital signs (resting systolic blood pressure, and heart rate), 6MWT distance (6MWTd), brain-type natriuretic peptide (BNP)/N-terminal prohormone of brain natriuretic peptide, and renal insufficiency (by estimated glomerular filtration rate).

Based on visual inspection, data were determined to be normally distributed. Continuous data are displayed as a mean ± SD and categorical data are displayed as number (% patient cohort). Paired samples Student t-test was used to compare distance covered (6MWTd), RPE, and lowest SpO$_2$ recorded during the 6MWT, pulmonary gas exchange responses to the submaximal CPET, echocardiographic-derived measures of right ventricular systolic pressure and right ventricular size and function, BNP concentration, and REVEAL Lite 2.0 score.

The acceptable type I error was set at $P < .05$, and all statistical analyses were performed using JMP version 14.1.0 (SAS Institute Inc., Cary, NC, USA).

RESULTS
Patient demographics are shown in Table 1; clinical data and submaximal CPET data are shown in Table 2. Test 1 and test 2 were performed consecutively and were separated by 81±51 days. Between test 1 and test 2, the patients were stable with no change in PAH disease severity as evidenced by no change in NYHA functional class, REVEAL Lite 2.0 score, BNP concentration, right ventricular systolic pressure, right ventricular function, and pulmonary gas exchange responses to the submaximal CPET (Table 2). The 6MWTd was not different between test 1 (without facemask) and test 2 (with facemasks) (405±108 m vs 400±103 m, $P = .81$). Similarly, both end-test RPE and lowest SpO$_2$ during the 6MWT were not different in test 1 versus test 2 (RPE: 2.5±1.7 vs 2.5±2.1, respectively, $P = .91$; SpO$_2$: 92.8±3.4% vs 93.3±3.3%, $P = .55$). In the patients who required the same amount of supplemental oxygen at both timepoints (n = 8; 17.8%), 6MWTd was not different between test 1 and test 2 (332±112 m vs 348±104 m, $P = .77$). Only three patients (6.7%) had a medication addition between the two time points.

DISCUSSION
The main finding of the present study was that in clinically stable PAH patients with...
Facemasks and 6-Minute Walk Test in PAH Patients

TABLE 2. Clinical Dataa,b

| Clinical data                  | Test 1   | Test 2   | P     |
|-------------------------------|----------|----------|-------|
| NYHA/WHA FC                   |          |          | .93   |
| I                             | 4 (8.9)  | 5 (11.1) |       |
| II                            | 17 (37.8)| 16 (35.6)|       |
| III                           | 24 (53.3)| 24 (53.3)|       |
| 6MWTd, m                      | 405±108  | 400±103  | .81   |
| 6MWT SpO2, %                  | 92.8±3.4 | 93.3±3.3 | .55   |
| RPE, Borg CR10                | 2.5±1.7  | 2.5±2.1  | .91   |
| REVEAL Lite 2 score           | 8.2±2.9  | 8.4±2.8  | .80   |
| BNP, pg/mL                    | 175±34  | 188±34  | .86   |
| RVSP, mm Hg                   | 55.7±15.8| 54.8±16.0| .80   |
| TAPSE, cm                     | 2.0±0.4  | 2.0±0.5  | .74   |
| RV enlargement                |          |          | .82   |
| None                          | 14 (31.8)| 17 (37.8)|       |
| Mild                          | 18 (40.9)| 15 (33.3)|       |
| Moderate                      | 7 (15.9)| 9 (20.0) |       |
| Severe                        | 5 (11.4)| 4 (8.9)  |       |
| RV dysfunction                |          |          | .97   |
| None                          | 25 (55.6)| 25 (55.6)|       |
| Mild                          | 11 (24.4)| 11 (24.4)|       |
| Moderate                      | 5 (11.1)| 6 (13.3) |       |
| Severe                        | 4 (8.9)| 4 (8.9)  |       |
| Submaximal CPET               |          |          |       |
| Resting SpO2, %               | 96±3     | 96±3     | .48   |
| V̇E/V̇CO₂ slope                | 38±0.97  | 38±1.11  | .74   |
| ΔPETCO₂, mm Hg                | 2.2±2.1  | 2.1±2.0  | .88   |

6MWT, 6-minute walk test; 6MWTd, 6-minute walk test distance; BNP, brain-type natriuretic peptide; CPET, cardiopulmonary exercise test; CR, category-ratio; NYHA/WHA FC, New York Heart Association/World Health Organization functional class; ΔPETCO₂, change in partial pressure of end-tidal CO₂ from start to end of submaximal CPET; SpO₂, arterial oxygen saturation; REVEAL, Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management; RPE, rating of perceived exertion at the point of 6MWT termination; RV, right ventricular; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion; V̇E/V̇CO₂, ventilatory equivalent for carbon dioxide.

aValues are number of patients (%) or group mean ± SD for 45 patients. Test 1 and test 2 were performed 81±51 days apart. Six-minute walk test (6MWT) at test 1 was performed without a facemask, whereas 6MWT at test 2 was performed with a facemask. A facemask was not worn during the submaximal cardiopulmonary exercise test (CPET) during either test 1 or test 2.

6MWTd and SpO₂ during the test provides adjunctive clinical information regarding functional status, disease severity and/or progression, and efficacy of therapeutic intervention.

Facemask function is, in part, determined by the resistance to airflow provided. Effective facemasks likely lower the risk of virus transmission between people in close proximity to each other secondary to a reduction in forward particle velocity in exhaled breath. This functionality has, however, led to concerns regarding facemask use during physical activity. It has been considered possible that such resistance to airflow could negatively impact pulmonary gas exchange and heighten breathlessness and breathing discomfort, especially during exercise; such reasoning is often cited when justifying facemask noncompliance. Despite these concerns, there is growing evidence that any negative effects of wearing a facemask during physical activity are negligible, and unlikely impact the thermal, cardiopulmonary (including heart rate, respiratory frequency, and pulmonary gas exchange), and perceptual responses to exercise.

Importantly, our data suggest that the distance covered (ie, exercise capacity), the perceptual response, and SpO₂ during a 6MWT are not negatively affected by the wearing of a facemask in clinically stable PAH patients with moderate-to-severe disease. Ventilatory inefficiency coupled with impaired pulmonary gas exchange and breathlessness during exercise is a hallmark of PAH. A number of signature breathing and gas exchange derangements, including a greater ventilatory equivalent for carbon dioxide, a blunted increase or even a decrease in the partial pressure of end-tidal CO₂ early in exercise, and exercise-related arterial hypoxemia become apparent during exercise in PAH patients. The etiology of these derangements in PAH is complex, but is likely related to ventilation-perfusion imbalances, physiological shunts, and an exaggerated ventilatory drive secondary to greater sensitivity of muscle ergoreceptors and/or central and peripheral chemoreceptors. As such, the present findings suggest that wearing a facemask is safe and has no deleterious impact on exercise capacity, even in a high-risk population who are predisposed to impaired exercise.
pulmonary gas exchange, heightened breathlessness, and exertional intolerance.

Two important questions remain: (1) Does wearing a facemask negatively impact exercise capacity when exercise is performed at a higher intensity? and (2) Does the type of face-mask used affect the physiological and perceptual responses to exercise? First, achieving a 6MWTd of ~400 m is approximately equivalent to 3.0 metabolic equivalents. That is, although patients are instructed to “walk as far as possible for 6 minutes,” the exercise intensity associated with a 6MWTd of ~400 m is possibly only moderate. Higher intensity exercise naturally requires higher minute ventilations. Whether the resistance to airflow provided by facemasks at such higher ventilatory rates negatively impacts exercise capacity requires further investigation. Second, N95 respirators provide greater airflow resistance compared to surgical and/or cloth facemasks. However, even at a relatively high minute ventilation (100 L·min⁻¹), it has been shown that the airflow provided by N95s is modest, and similar to the facemask and tubing used during standard cardiopulmonary exercise tests. Thus, it is perhaps unlikely that the physiological and perceptual responses to exercise with versus without a facemask are substantially altered by the type of facemask worn.

CONCLUSION
Our findings demonstrate that wearing a facemask has no discernable impact on the arterial oxygen saturation and perceptual responses to exercise or exercise capacity in patients with moderate-to-severe PAH. This study reinforces the evidence that facemasks are safe in PAH patients, even during exercise.

Abbreviations and Acronyms: 6MWT, 6-minute walk test; 6MWTd, 6-minute walk test distance; BNP, brain-type natriuretic peptide; CPET, cardiopulmonary exercise test; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; RPE, rating of perceived exertion; SpO₂, arterial oxygen saturation

Potential Competing Interests: The authors report no potential competing interests.

Correspondence: Address to Scott A. Helgeson, MD, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL (Helgeson.scott@mayo.edu).

ORCID
Scott A. Helgeson: https://orcid.org/0000-0001-7590-2293; Charles D. Burger: https://orcid.org/0000-0002-4815-3669

REFERENCES
1. Geldsetzer P. Use of rapid online surveys to assess people’s perceptions during infectious disease outbreaks: A cross-sectional survey on COVID-19. J Med Internet Res. 2020; 22(4):e18790.
2. Liang M, Gao L, Cheng C, et al. Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;36:10171.
3. Whelby WUaGL. Community use of face masks and COVID-19: evidence from a natural experiment of state mandates in the US. Health Affairs (Milwood). 2020;39(8):1419-1425.
4. CNN. Angry residents erupt at meeting over new mask rule. 2020. https://www.cnn.com/videos/politics/2020/06/24/mask-mandate-florida-anger-erupts-coronavirus-vpx.cnn. Accessed February 13, 2021.
5. Organization WH. Advice on the use of masks in the context of COVID-19: interim guidance. 2020. https://apps.who.int/iris/bitstream/handle/10665/332933/WHO-2019-nCoV-IPC-Mask-2020.4-eng.pdf?sequence=1&isAllowed=y. Accessed February 13, 2021.
6. Samannan R, Holt G, Calderon-Candelario R, Mirsaedi M, Campos M. Effect of face masks on gas exchange in healthy persons and patients with COPD. Ann Am Thorac Soc. 2021; 18(3):541-544.
7. Reberge Rj, Kim Jh, Benson Sm. Absence of consequential changes in physiological, thermal and subjective responses from wearing a surgical mask. Respir Physiol Neurobiol. 2012; 181(1):29-35.
8. Mapelli M, Salvioni E, De Martino F, et al. “You can leave your mask on”: effects on cardiopulmonary parameters of different airway protection masks at rest and during maximal exercise. Eur Respir J. 2021. https://doi.org/10.1183/13993003.04473-2020.
9. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):11-117.
10. Woods Pr, Frantz Rp, Taylor Bj, Olson Tp, Johnson Bd. The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. J Heart Lung Transplant. 2011; 30(10):1133-1142.
11. Woods Pr, Taylor Bj, Frantz Rp, Johnson Bd. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension. Am J Cardiol. 2012;109(7):1066-1072.
12. Benza Rl, Kanwar Mr, Rana A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator; REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337-346.
13. Kahler Cj, Hain R. Fundamental protective mechanisms of face masks against droplet infections. J Aerosol Sci. 2020;148:105617.
14. Hopkins Sr, Domineili Pb, Davis Ck, et al. Facemasks and the cardiopulmonary response to physical activity in health and disease. Ann Am Thorac Soc. 2021;18(3):399-407.
15. Otulana B, Higenbottom T. The role of physiological deadspace and shunt in the gas exchange of patients with pulmonary hypertension: a study of exercise and prostacyclin infusion. Eur Respir J. 1988;1(8):732-737.
16. American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. 10th ed. Philadelphia, PA: Wolters Kluwer; 2017.